Versanis Bio logo

Versanis Bio Funding & Investors

Versanis Bio is advancing bimagrumab, a human monoclonal antibody to the activin type II receptors that blocks the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies bimagrumab treatment consistently and potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters.

versanisbio.com

Total Amount Raised: $70,000,000

Versanis Bio Funding Rounds

  • Series A

    $70,000,000

    Series A Investors

    Atlas Venture
    Medicxi Ventures
    Aditum Bio
    TCG Crossover Management
Funding info provided by Diffbot.